Literature DB >> 25693967

Serious cardiac complications in coronary spasm provocation tests using acetylcholine or ergonovine: analysis of 21 512 patients from the diagnosis procedure combination database in Japan.

Toshiaki Isogai1, Hideo Yasunaga, Hiroki Matsui, Hiroyuki Tanaka, Tetsuro Ueda, Hiromasa Horiguchi, Kiyohide Fushimi.   

Abstract

BACKGROUND: Previous studies on complications with coronary spasm provocation tests were based on small sample sizes or were limited to high-volume centers. The risk of provocation tests using acetylcholine (ACH) or ergonovine (ER) remains to be fully examined by a large-scale multicenter study. HYPOTHESIS: ACH provocation tests are associated with a higher rate of serious cardiac complications than ER tests.
METHODS: Using the Diagnosis Procedure Combination database in Japan, we identified patients aged ≥20 years who underwent a pharmacological provocation test during coronary angiography. We assessed the composite outcome of cardiac complications requiring urgent procedures (defibrillation, chest compression, intra-aortic balloon pumping, or extracorporeal membrane oxygenation) or death on the day of the provocation test, and compared the outcome between ACH and ER tests.
RESULTS: Of 21 512 eligible patients in 602 hospitals, 10 628 (49.4%) underwent an ACH test and 10 884 (50.6%) underwent an ER test. The composite outcome occurred in 141 (0.7%) patients. The ACH group was significantly more likely to have the composite outcome than the ER group (0.9% vs 0.4%, P < 0.001). The propensity-score analyses showed consistent results (propensity score-matched, 0.9% vs 0.4%, P = 0.003; inverse probability-weighted, 0.8% vs 0.4%, P < 0.001). In a multivariable logistic regression analysis, ACH tests were significantly associated with a higher rate of the composite outcome than ER tests (odds ratio: 1.75, 95% confidence interval: 1.13-2.69, P = 0.011).
CONCLUSIONS: This retrospective cohort study suggested that ACH tests were associated with a higher rate of cardiac complications than ER tests.
© 2015 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25693967      PMCID: PMC6711001          DOI: 10.1002/clc.22369

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  5 in total

1.  Paroxysmal atrial fibrillation during intracoronary acetylcholine provocation test.

Authors:  Yuichi Saito; Hideki Kitahara; Toshihiro Shoji; Satoshi Tokimasa; Takashi Nakayama; Kazumasa Sugimoto; Yoshihide Fujimoto; Yoshio Kobayashi
Journal:  Heart Vessels       Date:  2016-12-22       Impact factor: 2.037

Review 2.  Acetylcholine Use in Modern Cardiac Catheterization Laboratories: A Systematic Review.

Authors:  Andrea Marrone; Rita Pavasini; Ennio Scollo; Federico Gibiino; Graziella Pompei; Serena Caglioni; Simone Biscaglia; Gianluca Campo; Matteo Tebaldi
Journal:  J Clin Med       Date:  2022-02-21       Impact factor: 4.241

3.  Fatal Vasospasm of the Coronary Arteries in a Patient Undergoing Distal Bypass Surgery and Endovascular Therapy for Threatened Lower Limbs Due to Acute Exacerbation of Peripheral Arterial Disease.

Authors:  Daisuke Takeyoshi; Shinsuke Kikuchi; Keisuke Miyake; Takamitsu Tatsukawa; Daita Kobayashi; Daiki Uchida; Yuya Kitani; Hiroyuki Kamiya; Nobuyoshi Azuma
Journal:  Ann Vasc Dis       Date:  2018-09-25

Review 4.  A Practical Approach to Invasive Testing in Ischemia With No Obstructive Coronary Arteries (INOCA).

Authors:  Alexandra Bastiany; Christine Pacheco; Tara Sedlak; Jaqueline Saw; Steven E S Miner; Shuangbo Liu; Andrea Lavoie; Daniel H Kim; Martha Gulati; Michelle M Graham
Journal:  CJC Open       Date:  2022-05-04

Review 5.  Myocardial Ischemic Syndromes, Heart Failure Syndromes, Electrocardiographic Abnormalities, Arrhythmic Syndromes and Angiographic Diagnosis of Coronary Artery Spasm: Literature Review.

Authors:  Ming-Yow Hung; Nicholas G Kounis; Meng-Ying Lu; Patrick Hu
Journal:  Int J Med Sci       Date:  2020-04-27       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.